Abbott Labs Posts New High on FDA Approval (ABT)

Photo of Paul Ausick
By Paul Ausick Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Health care products maker Abbott Laboratories (NYSE: ABT) received US Food and Drug Administration approval to market its new glucose monitoring system for the nearly 26 million US diabetics who take insulin. The company said the device would be available in the US “in the coming months.”

Shares are up 2.45% at $57.64, after posting a new 52-week high of $57.66 earlier.

Contact [email protected] for any questions or corrections.

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

SMCI Vol: 166,040,003
DELL Vol: 6,243,947
HPE Vol: 22,395,167
STX Vol: 4,732,264
ANET Vol: 10,008,622

Top Losing Stocks

CTRA Vol: 73,319,495
TPL Vol: 505,241
COR Vol: 2,611,047
FSLR Vol: 3,071,616
AXON Vol: 1,079,711